Tandem high-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuro-ectodermic tumors

2014 ◽  
Vol 61 (8) ◽  
pp. 1398-1402 ◽  
Author(s):  
Christelle Dufour ◽  
Virginie Kieffer ◽  
Pascale Varlet ◽  
Marie Anne Raquin ◽  
Frederic Dhermain ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Newly Diagnosed ◽  
Stem Cell Rescue ◽  
Autologous Stem Cell Rescue

scholarly journals Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma

2014 ◽  
Vol 61 (8) ◽  
pp. 1350-1356 ◽  
Author(s):  
Alissa Martin ◽  
Jennifer Schneiderman ◽  
Irene B. Helenowski ◽  
Elaine Morgan ◽  
Kimberley Dilley ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
High Dose Chemotherapy ◽  
Malignant Neoplasms ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Autologous Stem Cell Rescue

High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Children and Adults With Newly Diagnosed Pineoblastomas

2003 ◽  
Vol 21 (11) ◽  
pp. 2187-2191 ◽  
Author(s):  
Sridharan Gururangan ◽  
Colleen McLaughlin ◽  
Jennifer Quinn ◽  
Jeremy Rich ◽  
David Reardon ◽  
...  
Keyword(s):  
Stem Cell ◽  
Metastatic Disease ◽  
Tumor Resection ◽  
Disease Recurrence ◽  
High Dose Chemotherapy ◽  
Pineal Region ◽  
High Dose ◽  
Newly Diagnosed ◽  
Stem Cell Rescue ◽  
Autologous Stem Cell Rescue

Purpose: We evaluated the usefulness of a treatment regimen that included high-dose chemotherapy (HDC) with autologous stem-cell rescue (ASCR) in patients with newly diagnosed pineoblastoma (PBL). Patients and Methods: Twelve patients with PBL were initially treated with surgery and induction chemotherapy. All but two patients underwent radiotherapy. Subsequently, all patients received HDC using cyclophosphamide (CTX) + melphalan (MEL) or busulfan (Bu) + MEL regimens and ASCR. Results: A total of six children and six adults with median ages of 4.2 (range, 0.3 to 19.8 years) and 23 years (range, 23 to 43.7 years), respectively, were treated according to this strategy. Four patients had metastatic disease confined to the neuraxis. Five of 12 patients (42%) had a complete tumor resection at diagnosis. Ten patients received radiotherapy at median doses of 36.0 and 59.4 Gy to the neuraxis and pineal region, respectively. Eleven patients received HDC with CTX + MEL, and one patient received BU + MEL followed by ASCR. Nine patients are alive with no evidence of disease recurrence at a median of 62 months from diagnosis (range, 28 to 125 months), including three patients with metastatic disease and two infants who did not receive any radiotherapy. Three patients have died of progressive disease at 19, 32, and 37 months from diagnosis, respectively. The actuarial 4-year progression-free and overall survivals are 69% (95% confidence interval [CI], 39% to 99%) and 71% (95% CI, 43% to 99%), respectively. Conclusion: The use of HDC in addition to radiotherapy seems to be an effective treatment for patients with newly diagnosed pineoblastoma.

High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors

2005 ◽  
Vol 71 (1) ◽  
pp. 33-38 ◽  
Author(s):  
Antonio P�rez-Mart�nez ◽  
Alvaro Lassaletta ◽  
Marta Gonz�lez-Vicent ◽  
Juli�n Sevilla ◽  
Miguel Angel D�az ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Primitive Neuroectodermal Tumors ◽  
Stem Cell Rescue ◽  
Neuroectodermal Tumors ◽  
Autologous Stem Cell Rescue
Sign in / Sign up

Export Citation Format

Share Document